Variation at Interleukin-10 Locus Represents Susceptibility to Psoriasis in North Indian Population

Author(s): Wani Aadil, Rajinder Kaur*, Bashir Ahmad Ganai, Tahseena Akhtar, Tarun Narang, Iffat Hassan, Sunil Kumar.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 19 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: IL-10 is an important pleiotropic, immunoregulatory and anti-inflammatory cytokine which plays a significant role in the pathogenesis of psoriasis.

Objective: The aim of the present study was to determine whether the three polymorphic sites of the IL-10 gene, haplotype and serum level confer susceptibility to psoriasis.

Method: 200 psoriatic patients and 200 controls were genotyped for three IL-10 polymorphic sites by ARMS polymerase chain reaction. Serum levels of IL -10 were measured by ELISA.

Results: Our results demonstrated that polymorphism of IL-10 -592 C/A (adjusted* OR = 9.25; 95% CI =3.16- 27.06) and IL-10 1082 A/G (adjusted* OR = 4.28; (95% CI =1.46- 12.56) was found to be in association with increased risk of psoriasis while as IL- 10 819 C/T (adjusted* OR= 1.60; (95% CI = 0.65-3.95) polymorphism does not show any significant association with the risk of psoriasis. HT7 GTC haplotype is associated with increased risk of psoriasis. Serum levels of IL-10 were found to be significantly low in patients, as compared to controls with a non-significant correlation between serum IL-10 level and psoriasis severity.

Conclusion: IL-10 polymorphism imparted significant risk towards the development of psoriasis in North Indian population. Highlighting the role of IL-10 cytokine in the pathogenesis of psoriasis will help in the development of psoriasis management.

Keywords: Psoriasis, IL-10 polymorphism, ARMS PCR, ELISA, pleiotropic, cytokine.

[1]
Bhalerao, J.; Bowcock, A.M. The genetics of psoriasis: A complex disorder of the skin and immune system. Hum. Mol. Genet., 1998, 7(10), 1537-1545.
[2]
Lee, K.H.; Son, M.K.; Ha, Y.J.; Choi, S.T.; Lee, S.W.; Park, Y.B.; Lee, S.K. Inflammatory polyarthritis in a patient with psoriasis: Is it psoriatic arthritis or rheumatoid arthrirtis? Korean J. Intern. Med., 2010, 25(2), 224-226.
[3]
Dogra, S.; Yadav, S. Psoriasis in India: Prevalence and pattern. Indian J. Dermatol. Venereol. Leprol., 2010, 76(6), 595-601.
[4]
Westendorp, R.G.; Langermans, J.A.; Huizinga, T.W.; Elouali, A.H.; Verweij, C.L.; Boomsma, D.I.; Vandenbrouke, J.P. Genetic influence on cytokine production and fatal meningococcal disease. The Lancet, 1997, 349(9046), 170-173.
[5]
Trifunović, J.; Miller, L.; Debeljak, Ž.; Horvat, V. Pathologic patterns of interleukin 10 expression-A review. Biochemia medica, 2015, 25(1), 36-48.
[6]
Lee, Y.H.; Choi, S.J.; Ji, J.D.; Song, G.G. Associations between interleukin-10 polymorphisms and susceptibility to psoriasis: A meta-analysis. Inflamm. Res., 2012, 61(7), 657-663.
[7]
Rood, M.; Keijsers, V.; Van Der Linden, M.; Tong, T.; Borggreve, S.; Verweij, C.; Breedveld, F.; Huizinga, T. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann. Rheum. Dis., 1999, 58(2), 85-89.
[8]
Settin, A.; Hassan, H.; El-Baz, R.; Hassan, T. Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. Acta Dermatovenerol. Alp. Panonica Adriat., 2009, 18(3), 105-112.
[9]
Baran, W.; Szepietowski, J.C. MAzur, G.; Baran, E. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm. Venereol., 2008, 88(2), 113-116.
[10]
Wongpiyabovorn, J.; Hirankarn, N.; Ruchusatsawat, K.; Yooyongsatit, S.; Asawanonda, P.; Poovorawan, Y. Association of the interleukin‐10 distal promoter (‐2763A/C) polymorphism with late‐onset psoriasis. Clin. Exp. Dermatol., 2008, 33(2), 186-189.
[11]
Chang, Y.; Chou, C.; Yu, C.; Lin, M.; Shiao, Y.; Chen, C.; Huang, C.; Lee, D.; Liu, H.; Wang, W. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br. J. Dermatol., 2007, 156(5), 899-905.
[12]
Peddle, L.; Butt, C.; Snelgrove, T.; Rahman, P. Interleukin (IL) 1α, IL1β, IL receptor antagonist, and IL10 polymorphisms in psoriatic arthritis. Ann. Rheum. Dis., 2005, 64(7), 1093-1094.
[13]
Al‐Heresh, A.; Proctor, J.; Jones, S.; Dixey, J.; Cox, B.; Welsh, K.; McHugh, N. Tumour necrosis factor‐α polymorphism and the HLA‐Cw* 0602 allele in psoriatic arthritis. Rheumatology, 2002, 41(5), 525-530.
[14]
Craven, N.; Jackson, C.; Kirby, B.; Perrey, C.; Pravica, V.; Hutchinson, I.; Griffiths, C. Cytokine gene polymorphisms in psoriasis. Br. J. Dermatol., 2001, 144(4), 849-853.
[15]
Sambrook, J.; Russell, D.W. Purification of nucleic acids by extraction with phenol: Chloroform. CSH Protoc. 2006.
[16]
Kingo, K.; Koks, S.; Silm, H.; Vasar, E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun., 2003, 4(6), 455-457.
[17]
Karam, R.A.; Zidan, H.E.; Khater, M.H. Polymorphisms in the TNF-α and IL-10 gene promoters and risk of psoriasis and correlation with disease severity. Cytokine, 2014, 66(2), 101-105.
[18]
Taga, K.; Tosato, G. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol., 1992, 148(4), 1143-1148.
[19]
Asadullah, K.; Sterry, W.; Stephanek, K.; Jasulaitis, D.; Leupold, M.; Audring, H.; Volk, H-D.; Döcke, W-D. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach. J. Clin. Invest., 1998, 101(4), 783-794.
[20]
Tarzi, M.; Klunker, S.; Texier, C.; Verhoef, A.; Stapel, S.; Akdis, C.; Maillere, B.; Kay, A.; Larche, M. Induction of interleukin‐10 and suppressor of cytokine signalling‐3 gene expression following peptide immunotherapy. Clin. Exp. Allergy, 2006, 36(4), 465-474.
[21]
Reich, K.; Zipprich, S.; Fuchs, T.; Neumann, C.; Westphal, G.; Schulz, T.; Müller, M.; Hallier, E. Combined analysis of polymorphisms of the tumor necrosis factor-α and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J. Invest. Dermatol., 1999, 113(2), 214-220.
[22]
Smith, A.; Keen, L.; Billingham, M.; Perry, M.; Elson, C.; Kirwan, J.; Sims, J.; Doherty, M.; Spector, T.; Bidwell, J. Extended haplotypes and linkage disequilibrium in the IL1R1–IL1A–IL1B–IL1RN gene cluster: Association with knee osteoarthritis. Genes Immun., 2004, 5(6), 451-460.
[23]
Crawford, D.C.; Nickerson, D.A. Definition and clinical importance of haplotypes. Annu. Rev. Med., 2005, 56, 303-320.
[24]
Jacob, S.E.; Nassiri, M.; Kerdel, F.A.; Vincek, V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm., 2003, 12(5), 309-313.
[25]
Borghi, A.; Fogli, E.; Stignani, M.; Melchiorri, L.; Altieri, E.; Baricordi, O.; Rizzo, R.; Virgili, A. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: Preliminary study on a possible correlation between generalized immune status, treatments and disease. Arch. Dermatol. Res., 2008, 300(10), 551-559.
[26]
Verghese, B.; Bhatnagar, S.; Tanwar, R.; Bhattacharjee, J. Serum cytokine profile in psoriasis-a case–control study in a tertiary care hospital from northern india. Indian J. Clin. Biochem., 2011, 26(4), 373-377.
[27]
Roussaki-Schulze, A.; Kouskoukis, C.; Petinaki, E.; Klimi, E.; Zafiriou, E.; Galanos, A.; Rallis, E. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int. J. Clin. Pharmacol. Res., 2004, 25(4), 169-173.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 1
Year: 2019
Page: [53 - 58]
Pages: 6
DOI: 10.2174/1871530318666180821161629
Price: $58

Article Metrics

PDF: 16
HTML: 4